DGAP-News: biolitec AG: group revenue amounts to Euro 21.1 million in the first half of the fiscal year 2012/13
(firmenpresse) - DGAP-News: biolitec AG / Key word(s): Half Year Results
biolitec AG: group revenue amounts to Euro 21.1 million in the first
half of the fiscal year 2012/13
26.03.2013 / 12:34
---------------------------------------------------------------------
Sales increase of 1.8 million compared to last year period - Trade of
shares of biolitec AG, Jena is terminated - biolitec
Unternehmensbeteiligungs I AG, Wien operates again under biolitec AG
Wien/Jena, March 26, 2013 - biolitec AG (ISIN AT0000A0VCT2), Vienna, listed
in the Entry Standard of the Frankfurt stock exchange, which merged with
biolitec AG, Jena, on 15 March 2013, achieved a group revenue of Euro 21.1
million in the first half of the fiscal year 2012/2013. Thereby, the
revenue was Euro 1.8 million above the same period in the previous year.
The revenue growth of more than 9.1% is attributable to the growing demand
for biolitec's mainstays of sales, e.g. the endoluminal laser treatment of
veins (ELVeS-Radial(TM)). With this method, the damaged vein is treated
with laser light, and the vein is broken down by the body. The injection
port for the fibre is the only entrance point needed, so that nearly no
scars remain. In comparison to conventional therapies, e.g. stripping, the
prevention of post-operative discomforts is one of the outstanding features
of the ELVeS Radial(TM) laser therapy. New therapies such as the
outstanding new development in gynaecology, the revolutionary laser system
HOLA(TM) (Hysteroscopic Outpatient Laser Applications) for the treatment of
myomas, or the laser therapy for haemorrhoids of higher grades, the so
called Laser HaemorrhoidoPlasty (LHP(TM)), receive positive responses from
medicals and patients alike.
The gross profit amounted to Euro 15.0 million (previous year: Euro 12.0
million) and EBIT increased to Euro 1.4 million (previous year: Euro 0.92
million).
R&D expenditures for the first half of the fiscal year 2012/2013 of Euro
1.7 million (about 8% of sales) compared to the previous year (Euro 1.9
million) remain unchanged (in terms of percentage) on the required level to
ensure the company's long term growth and profitability. Sales costs were
increased to Euro 6.0 million (compared to Euro 5.5 million in the last
year's period). Earnings per share were at Euro 0.10 in comparison to Euro
0.06 in the same period of the previous year.
Major revenues of biolitec AG, Jena resp. Vienna, were generated in Europe
and North America. With Euro 7.3 million, sales in North America increased
by +1% compared to previous year's level. European sales amounted to Euro
7.4 million (previous year: Euro 7.8 million). Our foreign subsidiaries,
especially in the Arabian region and Asia, contribute increasingly to
overall results and showed pleasingly high growth rates of +45% to Euro 6.4
million in comparison to the first half of the previous year.
biolitec's medium-term goal to increase these markets' proportion of sales
up to one third and thus lay the basis of further growth adapted to the
world market situation could thus nearly be achieved in the first half of
the fiscal year 2012/2013.
Sales in the business segment Meditec increased by +12% to Euro 20.7
million in the first half of the year; in the Pharma segment, the sales
further amounted to modest Euro 0.14 million.
As already reported, the preparation of the annual financial statement
2011/2012 has been delayed longer than expected due to increased auditing
work and the merger process. biolitec has decided to publish the first half
of 2012/2013 even without available audit for the annual financial
statement 2011/2012 in order to provide its shareholders with the fullest
possible information about the company's situation.
In the meantime, the shares of biolitec AG (ISIN DE0005213409), Jena,
listed in the Prime Standard of the Frankfurt stock exchange, are removed
from trading due to the merger. The old shares of biolitec will be changed
to the new value in the Entry Standard into shares of biolitec AG (ISIN
AT0000A0VCT2) in the course of the merger. The trading of the new biolitec
shares will be resumed immediately after expiry of the corresponding
periods in the quality segment Entry Standard of the Frankfurt stock
exchange.
About biolitec(R):
biolitec(R) AG is one of the leading companies worldwide in the field of
medical laser treatments und the only provider that possesses all relevant
core competencies - photosensitizers, laser devices and optical fibres - in
the field of photodynamic therapy (PDT). Besides the laser treatment of
cancer with Foscan(R), biolitec(R) primarily researches on
minimally-invasive and gentle laser treatments and markets them. ELVeS
Radial(TM) (Endo Laser Vein System) the laser system is most often used
worldwide for the treatment of varicose veins. Ceralas(R) laser therapy
enables a gentle treatment of e.g. benign prostatic hyperplasia (BPH) in
urology. Gentle laser treatments in the fields of proctology, ENT,
orthopaedics, gynaecology as well as ophtalmology also belong to the
business field of biolitec(R). biolitec(R) AG (ISIN AT0000A0VCT2) is
listed in the Entry Standard. Further information at www.biolitec.de.
Investor Relations
Jörn Gleisner
Tel.: +49 (0) 3641/5195336
Fax: +49 (0) 3641/5195333
E-mail: joern.gleisner(at)biolitec.com
End of Corporate News
---------------------------------------------------------------------
26.03.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: biolitec AG
Parkring 2
A-1010 Wien
Austria
Phone: +49 (0) 3641 519 53 0
Fax: +49 (0) 3641 519 53 33
E-mail: info(at)biolitec.de
Internet: www.biolitec.at
ISIN: AT0000A0VCT2
WKN: A1JXLS
Listed: Frankfurt in Open Market (Entry Standard)
End of News DGAP News-Service
---------------------------------------------------------------------
205186 26.03.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.03.2013 - 12:34 Uhr
Sprache: Deutsch
News-ID 243011
Anzahl Zeichen: 7563
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 340 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: biolitec AG: group revenue amounts to Euro 21.1 million in the first half of the fiscal year 2012/13"
steht unter der journalistisch-redaktionellen Verantwortung von
biolitec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
